צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים ADC Therapeutics SA (ADCT)

The slow clinical adoption of Zynlonta and equity dilution are weighing on the finances of ADC Therapeutics (ADCT). The current level of quarterly EPS growth illustrates this trend, where the 45.50 mark serves as a critical threshold. Outsourced manufacturing ensures supply stability, while the development of targeted therapy relies on highly compensated scientists and generous stock option programs.
פילוחי מדדים מקיפים ואנליטיקה עבור ADC Therapeutics (ADCT)

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric allows for an assessment of capital management efficiency and business scaling rates. The quarterly EPS trend captured on GURU.Markets visualizes the cyclicality of the issuer's returns. For ADC Therapeutics (ADCT), this indicator reflects the financial success of the commercialization of the drug ZYNLONTA. A positive trend confirms the growing market share of targeted oncology therapy.